World's Largest Resource for Cardiovascular Perfusion

Perfusion StaffingPerfusion Staffing
   +1 888-499-5672Login
Perfusion NewswireECMO ZoneMobile Extracorporeal Membrane Oxygenation: 5-Year Experience of a French Pediatric and Neonatal Center

Mobile Extracorporeal Membrane Oxygenation: 5-Year Experience of a French Pediatric and Neonatal Center

ECMO Zone, Pediatric Zone, Perfusion Devices, Perfusion Zone, Tiny Perfusion Letter

Objectives

Extracorporeal membrane oxygenation is an established therapy for refractory cardiac and/or pulmonary failure that is not available in all centers. When infants and children require extracorporeal membrane oxygenation, they are sometimes placed on extracorporeal membrane oxygenation support in peripheral centers where extracorporeal membrane oxygenation is not available and then transferred on extracorporeal membrane oxygenation to specialized centers. The objective of this study is to first describe one of the largest cohorts of infants and children transported by a mobile unit while on extracorporeal membrane oxygenation.

Design

We undertook a single-center retrospective study that included patients transported while on extracorporeal membrane oxygenation between November 1, 2014, and May 31, 2019.

Patients

All patients transported by our mobile extracorporeal membrane oxygenation unit during the study period were included. Computerized data collection was approved by the French Data Protection Authority (Commission nationale de l’informatique et des libertés n° 2121127V0).

Main Results

Over the study period, our extracorporeal membrane oxygenation mobile team transported 80 patients on extracorporeal membrane oxygenation among which 20 were newborns (25%) and 60 were children of 1 month to 17 years old (75%); 57 patients were on venoarterial-extracorporeal membrane oxygenation (71%) and 23 on venovenous-extracorporeal membrane oxygenation (29%). The average duration of transport was 8.4 hours with a median of 8 hours; the average distance travelled was 189 ± 140 km. Transport was by air and then ground for 50% of the patients and by ground for 42%. We observed a significant decrease in the Vasoactive-Inotropic Score (125 vs 99; p = 0.005) and Paco2 levels (67 vs 49 mm Hg; p = 0.0005) after arrival in our unit. Survival rate 6 months after PICU discharge was 46% (37). There was a statistically significant relationship between initial lactate level and mortality (p = 0.02). We observed minor adverse events in 39% of the transports and had no mortality during transport.

Conclusions

We describe one of the largest cohorts of infants and children transported by a mobile unit while on extracorporeal membrane oxygenation. Our findings confirm that it is safe to start extracorporeal membrane oxygenation in a referring center and to transport patients using an extracorporeal membrane oxygenation mobile team. The only risk factor associated with higher mortality was an initially elevated lactate level.

Leave a Reply

You may also like

Biologics Zone, Main Zone

Single-Stage Sinus Augmentation With Cancellous Iliac Bone and Anorganic Bovine Bone in the Presence of Platelet-Rich Plasma in the Miniature Pig

Aim: The aim of the present study was to evaluate the osseointegration of dental implants and bone formation in maxillary sinus grafting with autologous and anorganic bovine bone in the presence of platelet-rich plasma (PRP) in an established animal model. Material and methods: We performed bilateral maxillary sinus augmentation with 50% anorganic bovine bone and simultaneously inserted a titanium screw implant in five minature pigs. Six hundred microlitre autologous PRP were added to the left side (test). The right side (no PRP) served as control. Polychrome sequential labeling was performed. The animals were sacrificed 6 weeks after surgery. Undecalcified ground sections were evaluated by microradiography, digitized histomorphometry and under fluorescent light. Results: The mean bone implant content in the test and control group was 8.4% and 17.3% respectively (P=0.042). The mean height of newly formed mineralized bone in the augmented area of the test group was 3.6 mm and 5.7 mm respectively (P=0.342). In the PRP group, the mean area of newly formed bone in the base of the sinus was enhanced (75.23%) as compared to the control side (51.8%) (P=0.020(*)). Although PRP enhanced bone formation at the base of the maxillary sinus, it neither improved osseointegration of dental implants nor bone in-growth into the bone substitute under the selected experimental conditions.

Join TodayJoin Today